Methylation of RAR? is a New Clinical Biomarker for Treatment in Higher-grade Gliomas

Basit Öğe Kaydı
dc.contributor.authorToprak, Cigdem
dc.contributor.authorAtli, Emine Ikbal
dc.contributor.authorKalkan, Rasime
dc.date.accessioned2024-06-12T11:02:42Z
dc.date.available2024-06-12T11:02:42Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: The dysregulation of various pathways and cellular processes contributes to the carcinogenic transition from low-grade gliomas to high-grade gliomas. The altered tumor microenvironment, altered epigenetic state, and high mutation heterogeneity are critical factors in glial tumors. The morphogen retinoic acid (RA) controls the homeostasis, regeneration, and development of the brain. RA receptor (RAR) gene methylation has been shown in different types of glial tumors. Aims and Objectives: This study assessed the RAR beta gene as a potential therapeutic target in gliomas. Materials and Methods: Using in silico methods, potential drugs targeting the RAR beta gene were compared based on temozolomide's effectiveness in treating gliomas. Results and Conclusion: Computational techniques can be used to identify drug-mediated pathways. This in silico study holds promise for RARB and RARB-targeted treatment strategies in gliomas.en_US
dc.identifier.doi10.4103/nsn.nsn_26_23
dc.identifier.endpage+en_US
dc.identifier.issn2636-865X
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85176410654en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage152en_US
dc.identifier.urihttps://doi.org/10.4103/nsn.nsn_26_23
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21382
dc.identifier.volume40en_US
dc.identifier.wosWOS:001107292600006en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofNeurological Sciences And Neurophysiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGlioma Treatmenten_US
dc.subjectRAR Betaen_US
dc.subjectTemozolomideen_US
dc.subjectPromoter Methylationen_US
dc.subjectStem-Cellsen_US
dc.subjectGlioblastomaen_US
dc.subjectMgmten_US
dc.subjectTemozolomideen_US
dc.subjectIdh1en_US
dc.subjectMutationsen_US
dc.subjectPathwaysen_US
dc.subjectToolen_US
dc.titleMethylation of RAR? is a New Clinical Biomarker for Treatment in Higher-grade Gliomasen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu